2026-04-17T17:19:59Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1231992025-12-05T16:29:32Zcom_2072_1057col_2072_478917col_2072_478921

A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS) Van Vollenhoven, Ronald F. Voskuyl, Alexandre E. Bertsias, George Aranow, Cynthia Aringer, Martin Arnaud, Laurent Askanase, Anca Balá ová, Petra Bonfa, Eloisa Bootsma, Hendrika Boumpas, Dimitrios Bruce, Ian N. Cervera i Segura, Ricard, 1960- Clarke, Ann E. Coney, Cindy Costedoat-Chalumeau, Nathalie Czirják, László Derksen, R. H. W. M. Doria, Andrea Dörner, Thomas Fischer-Betz, Rebecca Fritsch-Stork, Ruth Gordon, Caroline Graninger, Winfried Györi, Noémi Houssiau, Frédéric A. Isenberg, David Jacobsen, Søren Jayne, David Kuhn, Annegret Le Guern, Véronique Lerstrøm, Kirsten Levy, Roger A. Machado-Ribeiro, Francinne Mariette, Xavier Missaykeh, Jamil Morand, Eric Mosca, Marta Inanc, Murat Navarra, Sandra Lupus eritematós Malalties autoimmunitàries Farmacologia Estudi de casos Lupus erythematosus Autoimmune diseases Pharmacology Case studies Objectives Treat-to-target recommendations have identified 'remission' as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE. Methods An international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%. Results The task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions: 1. Definitions of remission will be worded as follows: remission in SLE is a durable state characterised by . (reference to symptoms, signs, routine labs). 2. For defining remission, a validated index must be used, for example, clinical systemic lupus erythematosus disease activity index (SLEDAI)=0, British Isles lupus assessment group (BILAG) 2004 D/E only, clinical European consensus lupus outcome measure (ECLAM)=0; with routine laboratory assessments included, and supplemented with physician's global assessment. 3. Distinction is made between remission off and on therapy: remission off therapy requires the patient to be on no other treatment for SLE than maintenance antimalarials; and remission on therapy allows patients to be on stable maintenance antimalarials, low-dose corticosteroids (prednisone ≤5 mg/day), maintenance immunosuppressives and/or maintenance biologics. The task force also agreed that the most appropriate outcomes (dependent variables) for testing the prognostic value (construct validity) of potential remission definitions are: death, damage, flares and measures of health-related quality of life. Conclusions The work of this international task force provides a framework for testing different definitions of remission against long-term outcomes. 2018-06-22T08:07:58Z 2018-06-22T08:07:58Z 2016-11-24 2018-06-22T08:07:58Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 0003-4967 https://hdl.handle.net/2445/123199 678610 27884822 eng Reproducció del document publicat a: https://doi.org/10.1136/annrheumdis-2016-209519 Annals of the Rheumatic Diseases, 2016, vol. 76, num. 3, p. 554-561 https://doi.org/10.1136/annrheumdis-2016-209519 (c) BMJ Publishing Group, 2016 info:eu-repo/semantics/openAccess 8 p. application/pdf BMJ Publishing Group Articles publicats en revistes (Medicina)